Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT)

Tan, Eddie; Aljurf, Mahmoud; Hussain, Fazal; Chabannon, Christian; Worel, Nina; Weisdorf, Daniel J.; Yakoub-Agha, Ibrahim; Galeano, Sebastian; Sánchez-Guijo, Fermín M.; Garderet, Laurent; Atsuta, Yoshiko; Ruggeri, Annalisa; Hamad, Nada; Hashmi, Shahruk; Frutos, Cristobal; Kodera, Yoshihisa; Seber, Adriana; Bonfim, Carmem; Niederwieser, Dietger; Rondelli, Damiano; Koh, Mickey

Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT)

Chimeric antigen receptor T cell therapy (CAR-T) cells represent a new generation of autologous, allogeneic and personalised cell-based therapies that have revolutionised the treatment of B cell haematological malignancies. Despite their significant effectiveness in treating challenging relapsed and...

ver descrição completa

Detalhes bibliográficos
Autores:	Tan, Eddie, Aljurf, Mahmoud, Hussain, Fazal, Chabannon, Christian, Worel, Nina, Weisdorf, Daniel J., Yakoub-Agha, Ibrahim, Galeano, Sebastian, Sánchez-Guijo, Fermín M., Garderet, Laurent, Atsuta, Yoshiko, Ruggeri, Annalisa, Hamad, Nada, Hashmi, Shahruk, Frutos, Cristobal, Kodera, Yoshihisa, Seber, Adriana, Bonfim, Carmem, Niederwieser, Dietger, Rondelli, Damiano, Koh, Mickey
Formato:	artículo
Estado:	Versión publicada
Fecha de publicación:	2025
País:	España
Recursos:	Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:	DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:	oai:dnet:digitalcsic_::e97db8c96c5a2ec661f29d556fedc5b2
Acesso em linha:	http://hdl.handle.net/10261/426305
Access Level:	acceso abierto
Palavra-chave:	CAR-T Chimeric antigen T cells Cellular therapy Haematopoietic stem cell transplant HSCT

id	ES_8b02439cc5b15ff2984d869d799cfaaa
oai_identifier_str	oai:dnet:digitalcsic_::e97db8c96c5a2ec661f29d556fedc5b2
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT)Tan, EddieAljurf, MahmoudHussain, FazalChabannon, ChristianWorel, NinaWeisdorf, Daniel J.Yakoub-Agha, IbrahimGaleano, SebastianSánchez-Guijo, Fermín M.Garderet, LaurentAtsuta, YoshikoRuggeri, AnnalisaHamad, NadaHashmi, ShahrukFrutos, CristobalKodera, YoshihisaSeber, AdrianaBonfim, CarmemNiederwieser, DietgerRondelli, DamianoKoh, MickeyCAR-TChimeric antigen T cellsCellular therapyHaematopoietic stem cell transplantHSCTChimeric antigen receptor T cell therapy (CAR-T) cells represent a new generation of autologous, allogeneic and personalised cell-based therapies that have revolutionised the treatment of B cell haematological malignancies. Despite their significant effectiveness in treating challenging relapsed and refractory diseases, access to this cutting-edge treatment remains a critical issue globally, even in high income countries. To gain insights into these challenges, the Worldwide Network for Blood & Marrow Transplantation (WBMT) initiated a survey focused on the state of CAR-T and cellular therapy availability worldwide. The survey aimed to identify the accessibility, manufacturing capabilities, apheresis, accreditation, reimbursement, presence of regulatory frameworks and legal oversight of these cell-based therapies. The survey included questions on demographics, the respondent's centre, CAR-T availability, details about haematopoietic stem cell transplant programs, supply and indications for CAR-T, quality assurance, and information about other cell and gene therapy products beside CAR-T. Conducted online over three months in 2023, the survey garnered 181 complete responses from various geographical regions, from North America, Asia, Europe, South and Central America, Australia and New Zealand, and Africa. Our findings suggested a promising level of awareness and interest in CAR-T therapy globally, even in lower-income regions. However, survey respondents cited cost as the primary barrier to access, alongside infrastructure and governmental support issues. The survey also highlighted the varying reimbursement strategies across regions, with costs in Europe and North America being relatively similar while Asia showed more variability. There was also variability in the regulatory and accreditation frameworks associated with delivery of these novel therapies As CAR-T therapy continues to grow, innovative solutions such as global partnerships, in-house production, and the establishment of cellular therapy centres in developing countries are essential. Addressing the challenges of access requires a comprehensive approach that combines efforts to lower costs, enhance healthcare infrastructure, and foster international collaborations, ensuring that CAR-T therapy becomes available to all who need it.Peer reviewedElsevierConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202620262025info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/426305reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttps://doi.org/10.1016/j.retram.2025.103515Síinfo:eu-repo/semantics/openAccessoai:dnet:digitalcsic_::e97db8c96c5a2ec661f29d556fedc5b22026-05-22T06:33:51Z
dc.title.none.fl_str_mv	Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT)
title	Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT)
spellingShingle	Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT) Tan, Eddie CAR-T Chimeric antigen T cells Cellular therapy Haematopoietic stem cell transplant HSCT
title_short	Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT)
title_full	Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT)
title_fullStr	Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT)
title_full_unstemmed	Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT)
title_sort	Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT)
dc.creator.none.fl_str_mv	Tan, Eddie Aljurf, Mahmoud Hussain, Fazal Chabannon, Christian Worel, Nina Weisdorf, Daniel J. Yakoub-Agha, Ibrahim Galeano, Sebastian Sánchez-Guijo, Fermín M. Garderet, Laurent Atsuta, Yoshiko Ruggeri, Annalisa Hamad, Nada Hashmi, Shahruk Frutos, Cristobal Kodera, Yoshihisa Seber, Adriana Bonfim, Carmem Niederwieser, Dietger Rondelli, Damiano Koh, Mickey
author	Tan, Eddie
author_facet	Tan, Eddie Aljurf, Mahmoud Hussain, Fazal Chabannon, Christian Worel, Nina Weisdorf, Daniel J. Yakoub-Agha, Ibrahim Galeano, Sebastian Sánchez-Guijo, Fermín M. Garderet, Laurent Atsuta, Yoshiko Ruggeri, Annalisa Hamad, Nada Hashmi, Shahruk Frutos, Cristobal Kodera, Yoshihisa Seber, Adriana Bonfim, Carmem Niederwieser, Dietger Rondelli, Damiano Koh, Mickey
author_role	author
author2	Aljurf, Mahmoud Hussain, Fazal Chabannon, Christian Worel, Nina Weisdorf, Daniel J. Yakoub-Agha, Ibrahim Galeano, Sebastian Sánchez-Guijo, Fermín M. Garderet, Laurent Atsuta, Yoshiko Ruggeri, Annalisa Hamad, Nada Hashmi, Shahruk Frutos, Cristobal Kodera, Yoshihisa Seber, Adriana Bonfim, Carmem Niederwieser, Dietger Rondelli, Damiano Koh, Mickey
author2_role	author author author author author author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv	Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv	CAR-T Chimeric antigen T cells Cellular therapy Haematopoietic stem cell transplant HSCT
topic	CAR-T Chimeric antigen T cells Cellular therapy Haematopoietic stem cell transplant HSCT
description	Chimeric antigen receptor T cell therapy (CAR-T) cells represent a new generation of autologous, allogeneic and personalised cell-based therapies that have revolutionised the treatment of B cell haematological malignancies. Despite their significant effectiveness in treating challenging relapsed and refractory diseases, access to this cutting-edge treatment remains a critical issue globally, even in high income countries. To gain insights into these challenges, the Worldwide Network for Blood & Marrow Transplantation (WBMT) initiated a survey focused on the state of CAR-T and cellular therapy availability worldwide. The survey aimed to identify the accessibility, manufacturing capabilities, apheresis, accreditation, reimbursement, presence of regulatory frameworks and legal oversight of these cell-based therapies. The survey included questions on demographics, the respondent's centre, CAR-T availability, details about haematopoietic stem cell transplant programs, supply and indications for CAR-T, quality assurance, and information about other cell and gene therapy products beside CAR-T. Conducted online over three months in 2023, the survey garnered 181 complete responses from various geographical regions, from North America, Asia, Europe, South and Central America, Australia and New Zealand, and Africa. Our findings suggested a promising level of awareness and interest in CAR-T therapy globally, even in lower-income regions. However, survey respondents cited cost as the primary barrier to access, alongside infrastructure and governmental support issues. The survey also highlighted the varying reimbursement strategies across regions, with costs in Europe and North America being relatively similar while Asia showed more variability. There was also variability in the regulatory and accreditation frameworks associated with delivery of these novel therapies As CAR-T therapy continues to grow, innovative solutions such as global partnerships, in-house production, and the establishment of cellular therapy centres in developing countries are essential. Addressing the challenges of access requires a comprehensive approach that combines efforts to lower costs, enhance healthcare infrastructure, and foster international collaborations, ensuring that CAR-T therapy becomes available to all who need it.
publishDate	2025
dc.date.none.fl_str_mv	2025 2026 2026
dc.type.none.fl_str_mv	info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 Publisher's version info:eu-repo/semantics/publishedVersion
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	http://hdl.handle.net/10261/426305
url	http://hdl.handle.net/10261/426305
dc.language.none.fl_str_mv	Inglés
language_invalid_str_mv	Inglés
dc.relation.none.fl_str_mv	https://doi.org/10.1016/j.retram.2025.103515 Sí
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	Elsevier
publisher.none.fl_str_mv	Elsevier
dc.source.none.fl_str_mv	reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str	Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str	DIGITAL.CSIC. Repositorio Institucional del CSIC
collection	DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869412775656161281
score	15,81155

Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT)

Registos relacionados